CMC Biologics has entered into an agreement with the University of Copenhagen for the process development and cGMP clinical production of VAR2CSA, a vaccine for placental malaria. The project aims to develop a prophylactic vaccine to protect women against malaria during pregnancy. The VAR2CSA molecule, developed by the University of Copenhagen, has the potential to significantly reduce the effects of the parasite.   ExpreS2ion Biotechnologies, a partner of Copenhagen University in placental mala...